Newron Pharmaceuticals SpA Total Liabilities
Newron Pharmaceuticals SpA total liabilities. Based on the latest financial reports, Newron Pharmaceuticals SpA (NWRN) has total liabilities worth CHF51.15 Million CHF (≈ $64.67 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check NWRN asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Newron Pharmaceuticals SpA (2005–2025)
Total liabilities of Newron Pharmaceuticals SpA from 2005 to 2025. This chart illustrates how Newron Pharmaceuticals SpA's total liabilities have evolved over time, based on quarterly financial data. Explore long-term investment intensity of Newron Pharmaceuticals SpA to see how much of total assets are deployed in long-term investments.
Newron Pharmaceuticals SpA Competitors by Total Liabilities
The table below lists competitors of Newron Pharmaceuticals SpA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tivan Ltd
AU:TVN
|
Australia | AU$13.44 Million |
|
Ningbo GQY Video Telecom
SHE:300076
|
China | CN¥124.40 Million |
|
Chongqing Wanli New Energy Co Ltd
SHG:600847
|
China | CN¥45.97 Million |
|
Launchpad Cadenza Acquisition Corp I Class A Ordinary Share
NASDAQ:LPCV
|
USA | $11.06 Million |
|
United Orthopedic
TWO:4129
|
Taiwan | NT$4.51 Billion |
|
Tatry Mountain Resorts a.s.
PR:TMR
|
Czech Republic | Kč453.90 Million |
|
Vine Hill Capital Investment Corp. II Class A Ordinary Shares
NASDAQ:VHCP
|
USA | $8.47 Million |
|
NexG Bhd
KLSE:5216
|
Malaysia | RM98.64 Million |
Liability Composition Analysis (2005–2025)
This chart breaks down Newron Pharmaceuticals SpA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see NWRN total assets.
Liquidity & Leverage Metrics
Newron Pharmaceuticals SpA Total Liabilities Ratios Explained
Newron Pharmaceuticals SpA total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.76 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -4.60 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Newron Pharmaceuticals SpA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Newron Pharmaceuticals SpA (2005–2025)
The table below shows the annual total liabilities of Newron Pharmaceuticals SpA from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CHF51.15 Million ≈ $64.67 Million |
-18.09% |
| 2024-12-31 | CHF62.45 Million ≈ $78.95 Million |
+11.97% |
| 2023-12-31 | CHF55.77 Million ≈ $70.51 Million |
+8.88% |
| 2022-12-31 | CHF51.23 Million ≈ $64.76 Million |
+8.12% |
| 2021-12-31 | CHF47.38 Million ≈ $59.90 Million |
+39.55% |
| 2020-12-31 | CHF33.95 Million ≈ $42.92 Million |
+44.54% |
| 2019-12-31 | CHF23.49 Million ≈ $29.70 Million |
+354.97% |
| 2018-12-31 | CHF5.16 Million ≈ $6.53 Million |
-2.64% |
| 2017-12-31 | CHF5.30 Million ≈ $6.70 Million |
-22.52% |
| 2016-12-31 | CHF6.84 Million ≈ $8.65 Million |
-5.83% |
| 2015-12-31 | CHF7.27 Million ≈ $9.19 Million |
-6.98% |
| 2014-12-31 | CHF7.81 Million ≈ $9.88 Million |
-25.79% |
| 2013-12-31 | CHF10.53 Million ≈ $13.31 Million |
-38.21% |
| 2012-12-31 | CHF17.04 Million ≈ $21.54 Million |
+144.08% |
| 2011-12-31 | CHF6.98 Million ≈ $8.83 Million |
+0.58% |
| 2010-12-31 | CHF6.94 Million ≈ $8.78 Million |
-44.00% |
| 2009-12-31 | CHF12.39 Million ≈ $15.67 Million |
-15.85% |
| 2008-12-31 | CHF14.73 Million ≈ $18.62 Million |
+13.58% |
| 2007-12-31 | CHF12.97 Million ≈ $16.40 Million |
-29.13% |
| 2006-12-31 | CHF18.30 Million ≈ $23.13 Million |
+182.52% |
| 2005-12-31 | CHF6.48 Million ≈ $8.19 Million |
-- |
About Newron Pharmaceuticals SpA
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's… Read more